Shares of Biopharma Company Up After Funding Offering

By: Dylan Sikes – AllPennyStocks.com News

Thursday, October 14, 2021

With a goal to develop novel therapies to prevent deaths and improve lives, this firm is at the forefront of the global fight against infections.

Appili Therapeutics (TSX:APLI) is an infectious disease biopharmaceutical company with a mission to solve life-threatening infections. The firm is part of a consortium sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19.

Funding proceeds will help with the firm’s Phase 3 PRESECO trial, which is evaluating an oral antiviral for the treatment of mild-to-moderate COVID-19, to deliver this critically needed medicine and hopefully change the trajectory of this pandemic.

Shares were trading up near 3% in afternoon trade.

Copyright © 2021 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.